Recent Quotes (30 days)

You have no recent quotes
chg | %

Nuvo Pharmaceuticals Inc  

(Public, TSE:NRI)   Watch this stock  
Find more results for NRI
-0.03 (-0.58%)
Apr 28 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 5.15 - 5.25
52 week 5.14 - 8.35
Open 5.20
Vol / Avg. 3,100.00/28,148.00
Mkt cap 59.72M
P/E 8.23
Div/yield     -
EPS 0.63
Shares 11.55M
Beta -0.67
Inst. own     -
May 9, 2017
Q1 2017 Nuvo Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
Mar 2, 2017
Q4 2016 Nuvo Pharmaceuticals Inc Earnings Call
Mar 1, 2017
Q4 2016 Nuvo Pharmaceuticals Inc Earnings Release
Jan 30, 2017
Nuvo Pharmaceuticals Inc at Noble Financial Emerging Growth Investor Conference

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin 31.20% 27.40%
Operating margin 28.96% 28.60%
EBITD margin - 28.92%
Return on average assets 26.39% 17.30%
Return on average equity 31.88% 20.42%
Employees 40 -
CDP Score - -


7560 Airport Rd Unit 10
+1-905-6736980 (Phone)
+1-905-6731842 (Fax)

Website links


Nuvo Pharmaceuticals Inc., formerly Nuvo Research Inc., is a Canada-based healthcare company. The Company offers a range of commercial products, including Pennsaid 2%, Pennsaid and the heated lidocaine/tetracaine (HLT) patch. The Company's Pennsaid 2% is a non-steroidal anti-inflammatory drug (NSAID) containing 2% diclofenac sodium. Its Pennsaid 2% is indicated for treating the pain of osteoarthritis (OA) of the knee and also acute strains and sprains. The Company's Pennsaid is a topical pain product, which is used to treat the signs and symptoms of OA of the knee. The Pennsaid combines the transdermal carrier with diclofenac sodium, which is a NSAID and delivers the active drug through the skin at the site of pain. Its HLT Patch is a topical patch that combines lidocaine, tetracaine and heat, using Controlled Heat-Assisted Drug Delivery (CHADD) technology. HLT Patch provides local analgesia prior to painful needle procedures, such as dialysis, blood draws and pediatric needles.

Officers and directors

Daniel H. Chicoine Chairman of the Board, Co-Chief Executive Officer
Jesse Ledger President
John C. London Co-Chief Executive Officer, Director
Mary-Jane Eleanor Burkett Chief Financial Officer, Vice President
Henrich R. K. Guntermann M.D. President of Europe and Immunology Group, Director
Katina Loucaides Vice President, General Counsel, Secretary
David A. Copeland Lead Independent Director
Samira Sakhia CPA Director
Anthony E. Dobranowski Independent Director
Jacques Messier Independent Director